

In the Claims:

Please cancel claims 72, 116 and 117 without prejudice or disclaimer.

1 – 70. (Canceled)

71. (Previously Presented) A process for treating a recipient of a transplant to reduce in said recipient an immune response of effector cells against a xenoantigen to the effector cells, comprising

administering to a recipient of a transplant mesenchymal stem cells in an amount effective to reduce an immune response of effector cells against a xenoantigen to the effector cells, whereby in the recipient the effector cells have a reduced immune response against the xenoantigen.

72 - 95. (Canceled)

96. (Previously Presented) The process of claim 71 wherein said effector cells are T cells.

97. (Previously Presented) The process of claim 96 wherein the T cells are from the donor and the xenoantigen is from the recipient.

98. (Previously Presented) The process of claim 71 wherein the T cells are from the recipient and the xenoantigen is from the donor.

99. (Previously Presented) The process of claim 71 wherein said T cells are present in a transplant.

100
~~101~~. (Previously Presented) The process of claim 71 wherein said MSCs are administered to a recipient of a transplant suffering from graft-versus-host disease.

126 ¹⁰¹
~~102.~~ (Previously Presented) The process of claim 71 wherein prior to said administration said mesenchymal stem cells (MSCs) have been expanded in culture.

¹⁰²
~~103.~~ (Previously Presented) The process of claim 71 wherein said effector cells are T cells previously activated and said immune response is the reactivation of said T cells.

¹⁰³
~~104.~~ (Previously Presented) The process of claim 71 wherein the transplant is skin.

¹⁰⁴
~~105.~~ (Previously Presented) The process of claim 71 wherein the mesenchymal stem cells are administered to the recipient to treat rejection of the transplant by the recipient.

¹⁰⁵
~~106.~~ (Previously Presented) The process of claim 71 wherein the mesenchymal stem cells are human mesenchymal stem cells.

¹⁰⁶
~~107.~~ (Previously Presented) The process of claim 71 further comprising administering to the recipient immunosuppressive agents.

¹⁰⁷
~~108.~~ (Previously Presented) The process of claim 71 wherein the transplant is a solid organ.

¹⁰⁸ ¹⁰⁷
~~109.~~ (Previously Presented) The process of claim ~~108~~ wherein the solid organ is selected from heart, pancreas, kidney, lung or liver.

¹⁰⁹
~~110.~~ (Previously Presented) The process of claim 71 wherein said mesenchymal stem cells are administered prior to said transplant.

¹¹⁰
~~111.~~ (Previously Presented) The process of claim 71 wherein said mesenchymal stem cells are administered concurrently with said transplant.

Rule
1.126
↓
¹¹¹
~~112~~. (Previously Presented) The process of claim 71 wherein said mesenchymal stem cells are administered as part of the transplant.

¹¹²
~~113~~. (Previously Presented) The process of claim 71 wherein the mesenchymal stem cells are administered subsequent to transplant.

¹¹³
~~114~~. (Previously Presented) The process of claim 71 wherein said mesenchymal stem cells are administered intravenously to the recipient.

¹¹⁴
~~115~~. (Previously Presented) The process of claim 71 wherein said effector cells are cells of a recipient of said donor transplant.

¹¹⁵⁻¹¹⁶
~~116-117~~. (Canceled)